Let's keep our fingers crossed, and if it comes to be, one of the more cruel diseases may be conquered or, at least, managed to a degree considered hitherto impossible.
BrainStorm Cell Therapeutics Inc. (OTC BB: BCLI), Israeli Channel 2 TV interviewed today a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking, balance, posture, muscle strength, appetite, digestion, and weight gain following compassionate treatment with BrainStorm's NurOwn cell therapy....And more:
BrainStorm expects to expand its ALS clinical development into the United States. Orphan-drug designation for NurOwn has been granted by the US Food and Drug Administration. In addition, the Company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these institutions.
BrainStorm Cell Therapeutics said the Mayo Clinic in Minnesota has agreed to conduct a clinical trial of the company's adult stem cell treatment for ALS. The Mayo Clinic is the third leading U.S. clinical site to sign a letter of understanding, following the University of Massachusetts and Massachusetts General, BrainStorm said on Monday.What else is left to say? Oh yes, and I hope that the treatment will become available in time to help our principled boycotter, Stephen Hawking, who used to support the ALS research in Israel.
About Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. According to the ALS Association, approximately 5,600 people in the U.S.are diagnosed with ALS each year and it is estimated that as many as 30,000 Americans may have the disease at any given time. The financial cost to families of patients is exceedingly high.
Hat tip: Shira.